CS17919 (0.32-10 μM; 72 hours) effectively protects LO2 cells treated with palmitic acid.

ASK1 x:22.52 nM

CS17919 (0.32-10 μM; 72 hours) effectively protects LO2 cells treated with palmitic acid.

CS17919 administered at dosages ranging from 10-60 mg/kg orally, twice daily for 11 days, has been shown to enhance kidney function and reduce fibrosis in a unilateral ureteral obstruction (UUO) model. When provided at 50 mg/kg, orally, twice daily for 70 days, the compound significantly mitigates glomerular sclerosis in the diabetic kidney disease (DKD) model. Furthermore, at a dose of 20 mg/kg, orally given twice daily for four weeks, CS17919 substantially improves hepatic inflammation and fibrosis in a non-alcoholic steatohepatitis (NASH) model. Pharmacokinetic parameters in C57BL/6J mice demonstrate that CS17919 maintains effective drug concentrations over time with the following measured values: AUC 0–∞ (h·ng/mL) ranging from 23,113 ± 5898.47 at 20 mg/kg to 58,795 ± 23,199.32 at 50 mg/kg; C max (ng/mL) from 4039 ± 646.90 at 20 mg/kg to 5741 ± 1835 at 50 mg/kg; with a T max (h) of 1.50 ± 0.87 at 20 mg/kg and 2.00 ± 0 at 50 mg/kg.